170 related articles for article (PubMed ID: 23902245)
21. [New treatments for castration-resistant prostate cancer].
Sautois B; Gennigens C
Rev Med Liege; 2013 Feb; 68(2):94-6. PubMed ID: 23469490
[TBL] [Abstract][Full Text] [Related]
22. Castrate-resistant prostate cancer: postdocetaxel management.
Zhao S; Yu EY
Curr Opin Urol; 2013 May; 23(3):201-7. PubMed ID: 23344012
[TBL] [Abstract][Full Text] [Related]
23. New treatment options for patients with metastatic prostate cancer.
Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
[TBL] [Abstract][Full Text] [Related]
24. Practical guide to the use of enzalutamide.
Hoffman-Censits J; Kelly WK
Can J Urol; 2014 Apr; 21(2 Supp 1):64-9. PubMed ID: 24775726
[TBL] [Abstract][Full Text] [Related]
25. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
Yin L; Hu Q; Hartmann RW
Int J Mol Sci; 2013 Jul; 14(7):13958-78. PubMed ID: 23880851
[TBL] [Abstract][Full Text] [Related]
26. Changing therapeutic paradigms in castrate-resistant prostate cancer.
Zivi A; Massard C; De-Bono J
Clin Genitourin Cancer; 2010 Dec; 8(1):17-22. PubMed ID: 21208851
[TBL] [Abstract][Full Text] [Related]
27. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
Zhang T; Zhu J; George DJ; Armstrong AJ
Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
[TBL] [Abstract][Full Text] [Related]
28. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
Schrader AJ; Boegemann M; Ohlmann CH; Schnoeller TJ; Krabbe LM; Hajili T; Jentzmik F; Stoeckle M; Schrader M; Herrmann E; Cronauer MV
Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
[TBL] [Abstract][Full Text] [Related]
29. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
Ouzaid I; Ravery V; Pouessel D; Culine S
Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
[TBL] [Abstract][Full Text] [Related]
30. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Cheng ML; Fong L
Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
[TBL] [Abstract][Full Text] [Related]
31. New treatment options for castrate-resistant prostate cancer: a urology perspective.
Gomella LG; Gelpi F; Kelly WK
Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
[TBL] [Abstract][Full Text] [Related]
32. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
Kinsey EN; Zhang T; Armstrong AJ
Cancer J; 2020; 26(1):64-75. PubMed ID: 31977388
[TBL] [Abstract][Full Text] [Related]
33. [Hormonal treatment in prostate cancer].
Bastide C; Bruyère F; Karsenty G; Guy L; Rozet F
Prog Urol; 2013 Nov; 23(15):1246-57. PubMed ID: 24183083
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.
Sumanasuriya S; De Bono J
Cold Spring Harb Perspect Med; 2018 Jun; 8(6):. PubMed ID: 29101113
[TBL] [Abstract][Full Text] [Related]
35. [How to manage patients with CRPC?].
Beuzeboc P; Massard C
Bull Cancer; 2015 Jun; 102(6):509-15. PubMed ID: 26028494
[TBL] [Abstract][Full Text] [Related]
36. New prostate cancer drugs hold promise.
Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
[No Abstract] [Full Text] [Related]
37. [Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
Westdorp H; Benoist GE; Schers HJ; van Erp PH; Gerritsen WR; Mulders PF; Kramers C
Ned Tijdschr Geneeskd; 2015; 159():A9250. PubMed ID: 26246066
[TBL] [Abstract][Full Text] [Related]
38. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
Hahn AW; Hale P; Rathi N; Agarwal N
Curr Opin Urol; 2017 Nov; 27(6):559-565. PubMed ID: 28816716
[TBL] [Abstract][Full Text] [Related]
39. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
40. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
